Rezolute Inc’s filing revealed that its Chief Medical Officer ROBERTS BRIAN KENNETH acquired Company’s shares for reported $1275.0 on Mar 28 ’24. In the deal valued at $2.55 per share,500 shares were bought. As a result of this transaction, ROBERTS BRIAN KENNETH now holds 1,076 shares worth roughly $3314.08.
Then, Evans Daron bought 20,000 shares, generating $33,830 in total proceeds. Upon buying the shares at $1.69, the CFO now owns 20,000 shares.
Before that, ROBERTS BRIAN KENNETH bought 10,000 shares. Rezolute Inc shares valued at $18,800 were divested by the Chief Medical Officer at a price of $1.88 per share. As a result of the transaction, ROBERTS BRIAN KENNETH now holds 10,000 shares, worth roughly $30800.0.
Maxim Group initiated its Rezolute Inc [RZLT] rating to a Buy in a research note published on April 09, 2024; the price target was $8. Cantor Fitzgerald began covering RZLT with “an Overweight” recommendation on June 15, 2022. ROTH Capital started covering the stock on September 08, 2021. It rated RZLT as “a Buy”.
Price Performance Review of RZLT
On Monday, Rezolute Inc [NASDAQ:RZLT] saw its stock jump 14.07% to $3.08. Over the last five days, the stock has gained 21.74%. Rezolute Inc shares have risen nearly 210.33% since the year began. Nevertheless, the stocks have risen 64.71% over the past one year. While a 52-week high of $2.75 was reached on 04/15/24, a 52-week low of $0.72 was recorded on 01/17/24. SMA at 50 days reached $1.83, while 200 days put it at $1.39. A total of 0.78 million shares were traded, compared to the trading of 0.26 million shares in the previous session.
Levels Of Support And Resistance For RZLT Stock
The 24-hour chart illustrates a support level at 2.76, which if violated will result in even more drops to 2.43. On the upside, there is a resistance level at 3.45. A further resistance level may holdings at 3.81. The Relative Strength Index (RSI) on the 14-day chart is 76.97, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.33, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 25.95%. Stochastics %K at 84.32% indicates the stock is a selling.
The most recent change occurred on May 27, 2021 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $25 price target.
